芪竹方改善早期胃癌ESD后症状及预防复发的临床观察
Clinical Observation on the Effects of Qizhu Formula in Improving Postoperative Symptoms of Early Gastric Cancer and Preventing the Recurrence of Gastric Cancer
-
摘要: 目的 观察芪竹方改善早期胃癌胃黏膜剥离术(ESD)后气阴两虚型症状及预防胃癌复发的临床疗效。方法 共84例早期胃癌ESD后气阴两虚证患者随机分成2组,其中脱落6例,纳入治疗组39例,对照组39例。对照组给予胃复春治疗,治疗组予芪竹方治疗,持续治疗1 a。观察2组临床复发率、胃镜像糜烂灶、病理积分、中医证候积分及癌胚抗原(CEA)变化。结果 治疗后,治疗组在复发率方面低于对照组(5.13% vs. 20.51%,P<0.05),治疗组可以较好地减少糜烂灶(P<0.01),降低病理积分及CEA水平(P<0.01),改善临床症状(P<0.01),均优于对照组(P<0.05)。结论 芪竹方可以较好地改善临床症状,减少胃黏膜糜烂、肠化生及异型增生,降低复发率,临床疗效显著。Abstract: OBJECTIVE To observe the efficacy of Qizhu formula in improving qi and yin deficiency symptoms after gastric endoscopic submucosal dissection (ESD) for patients with early gastric cancer and preventing the recurrence of gastric cancer. METHODS 84 patients with early gastric cancer who had deficiency of qi and yin symptoms were randomly divided into 2 groups with 6 expulsion cases, 39 cases in the treatment group and 39 cases in the control group after ESD. The control group was treated with Weifuchun pills, while the treatment group was treated with Qizhu decoction for one year. Clinical recurrence rate, gastroscopy erosions, pathological scores, traditional Chinese medicine (TCM) syndrome scores and carcinoembryonic antigen (CEA) changes were observed in the 2 groups. RESULTS After the treatment, the recurrence rate was lower in the treatment group than that in the control group (5.13% vs 20.51%, P<0.05). Compared with the control group, the treatment group had less clinical symptoms (P<0.01), erosions (P<0.05), lower pathological scores (P<0.05) and CEA (P<0.05), as well as significant relieves in stomachache, poor digestion and acid reflux symptoms (P<0.05). CONCLUSION Qizhu decoction can improve clinical symptoms, reduce gastric mucosal erosion, intestinal metaplasia and hyperplasia, and reduce the recurrence rate of gastric cancer with a remarkable therapeutic effect.
-
[1] Japanese Gastric Cancer Association.Japanese classification of gastric carcinoma:3rd English edition[J].Gastric Cancer,2011,14(2):101-112. [2] 中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:126-127. [3] 中华医学会消化病学分会.中国慢性胃炎共识意见(2017年,上海)[J].中华消化杂志,2017,37(11):721-738. [4] CHEN W,ZHENG R,BAADE PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132. [5] 北京市科委重大项目《早期胃癌治疗规范研究》专家组.早期胃癌内镜下规范化切除的专家共识意见(2018,北京)[J].中华消化内镜杂志,2019,36(6):381-392. [6] 刘树勋,陈明聪,江辉斌,等.注射用黄芪多糖联合EOF方案治疗晚期胃癌疗效分析[J].中国中西医结合消化杂志,2014,22(11):684-686. [7] 周平.沙参麦冬汤加味治疗胃阴不足型慢性萎缩性胃炎[J].养生保健指南,2017,9(26):248. [8] 冷秀梅,郭亚云,魏睦新.化痰消瘀方逆转胃癌癌前病变的临床疗效观察[J].中国中西医结合消化杂志,2013,21(10):505-508. [9] 王秋兰,薛永杰,韩涛.胃癌中CLIC4蛋白表达及白花蛇舌草总黄酮对其表达的影响[J].临床与实验病理学杂志,2016,32(6):681-684. [10] 王晓华,单兆伟.芪竹方对人胃腺癌MGC-803细胞Caspase-3及端粒酶增殖与凋亡的影响[J].中国中西医结合消化杂志,2006,14(2):90-92. [11] 陈曦,赵亚红,张也青,等.胃复春的临床应用和现代研究进展[J].江西中医药,2016,47(9):77-80. [12] 单兆伟,沈洪.单兆伟治疗脾胃病经验撷粹[M].北京:人民卫生出版社,2014:52. [13] 葛阳,张杨.谢晶日教授治疗胃癌的经验拾萃[J].实用中西医结合临床,2013,13(1):83-84. [14] 杨慧洁,杨世海,张海弢,等.玉竹化学成分、药理作用研究进展及开发利用现状[J].人参研究,2012,24(3):40-45.
点击查看大图
计量
- 文章访问数: 592
- HTML全文浏览量: 4
- PDF下载量: 836
- 被引次数: 0